Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis

Study identification

• EU PAS number:
  EUPAS1000001179
• Study ID:
  1000001179
• Official title and acronym:
  Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
• Study status:
  Finalised

Research institutions and networks

No information provided.

Study timelines

Date when funding contract was signed

Actual:18/04/2023

Study start date

Actual:18/04/2023

Date of final study report

Planned:01/12/2027

Actual:14/07/2023

Sources of funding

More details on funding

No information provided.

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

1199-0526; NCT05779007